NSABP FC-11: A phase II study of neratinib plus trastuzumab or neratinib plus cetuximab in patients with “quadruple wild-type” (KRAS/NRAS/BRAF/PIK3CA) metastatic colorectal cancer based on HER2 status: amplified, non-amplified (wild-type), or mutated

Authors: Kolevska, Tatjana | Cancer Chemotherapy And Pharmacology | August 9, 2025 | PubMed abstract

Explore all publications

Back To Top